Esra Salim Dogdas

Esra Salim Dogdas

Auto-generated profile, based on publicly available information

Esra Salim Dogdas

Department of Infectious Diseases and Clinical Microbiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 34147 Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
YOYusuf Emre Ozdemir
Yusuf Emre Ozdemir
EDEsra Salim Doğdaş
Esra Salim Doğdaş
ADAdile Sevde Demir
Adile Sevde Demir
Deniz BorcakDeniz Borcak
Deniz Borcak
EÜEsra Canbolat Ünlü
Esra Canbolat Ünlü
KYKadriye Kart Yaşar
Kadriye Kart Yaşar

18 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Deniz BorcakDeniz Borcak
Deniz Borcak
ZYZuhal Yesilbag
Zuhal Yesilbag
YOYusuf Emre Ozdemir
Yusuf Emre Ozdemir
ADAdile Sevde Demir
Adile Sevde Demir
EDEsra Salim Dogdas
Esra Salim Dogdas
KYKadriye Kart Yasar
Kadriye Kart Yasar
Background/Objectives: The accurate evaluation of the fibrosis stage is critical for improving chronic hepatitis B (CHB) management and patient outcomes. This study aimed to compare the diagnostic accuracy of non-invasive fibrosis markers with liver biopsy for detecting significant, advanced fibrosis and cirrhosis. We further investigated the diagnostic performance of non-invasive markers according to HBeAg status to provide further insight into their clinical utility across patient subgroups. Methods: This single-center retrospective study included 536 treatment-naive patients with CHB who underwent liver biopsy. Patients were categorized into four groups according to the fibrosis stage: “no significant fibrosis” (F0–F2), “significant fibrosis” (F3–F6), “advanced fibrosis” (F4–F6), and “cirrhosis” (F5–F6). AAR, AAPRI, APRI, API, FIB-4, GPR, and S–index were compared among these groups. Results: In total, 536 treatment-naïve patients were analyzed (63.2% male; mean age 44.8 ± 12.9 years), of whom 25.4% were HBeAg-positive. API, FIB 4, GPR, and S-Index showed good performance (area under the curve [AUC] ≥ 0.8–0.9) in defining advanced fibrosis (≥F4), AAPRI, AAR, API, and APRI showed good performance ([AUC] < 0.700) in defining cirrhosis. The analysis showed that GPR had the highest AUC for ≥F3 (0.719) and ≥F4 (0.838), while FIB 4 had the highest AUC for cirrhosis (0.865). Conclusions: These findings highlight the value of non-invasive markers as inexpensive and easily applicable methods for clinicians in assessing the stage of liver fibrosis. The integration of these scores into the routine monitoring of chronic hepatitis B patients is expected to expand, enhancing clinical decision-making and reducing the necessity for liver biopsies.